The Leading Community for Trusted Peptide Research & Insights
Join a vibrant community sharing real peptide experiences, clinical research, and proven protocols. Data-backed, open, and censorship-free.
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks. Currently in Phase 3 development.
Summary: Triple receptor agonist that activates GIP, GLP-1, and glucagon receptors, producing synergistic effects on appetite, metabolism, and energy expenditure. Mechanisms (reported/proposed across domains): Appetite & satiety • GLP-1 receptor activation suppresses appetite and delays gastric emptying, an established satiety pathway. • GIP receptor activation may complement satiety effects...
Investigational - Phase 3 Trials
Dose: 1–12 mg (titrated) · Route: Subcutaneous (SC) · Frequency: 1× weekly · Duration: 48+ weeks (clinical trials)
Join a vibrant community sharing real peptide experiences, clinical research, and proven protocols. Data-backed, open, and censorship-free.